title: Alendronate-coated long-circulating liposomes containing 99mtechnetium-ceftizoxime used to identify osteomyelitis.
abstract: Osteomyelitis is a progressive destruction of bones caused by microorganisms. Inadequate or absent treatment increases the risk of bone growth inhibition, fractures, and sepsis. Among the diagnostic techniques, functional images are the most sensitive in detecting osteomyelitis in its early stages. However, these techniques do not have adequate specificity. By contrast, radiolabeled antibiotics could improve selectivity, since they are specifically recognized by the bacteria. The incorporation of these radiopharmaceuticals in drug-delivery systems with high affinity for bones could improve the overall uptake. In this work, long-circulating and alendronate-coated liposomes containing (99m)technetium-radiolabeled ceftizoxime were prepared and their ability to identify infectious foci (osteomyelitis) in animal models was evaluated. The effect of the presence of PEGylated lipids and surface-attached alendronate was evaluated. The bone-targeted long-circulating liposomal (99m)technetium-ceftizoxime showed higher uptake in regions of septic inflammation than did the non-long-circulating and/or alendronate-non-coated liposomes, showing that both the presence of PEGylated lipids and alendronate coating are important to optimize the bone targeting. Scintigraphic images of septic or aseptic inflammation-bearing Wistar rats, as well as healthy rats, were acquired at different time intervals after the intravenous administration of these liposomes. The target-to-non-target ratio proved to be significantly higher in the osteomyelitis-bearing animals for all investigated time intervals. Biodistribution studies were also performed after the intravenous administration of the formulation in osteomyelitis-bearing animals. A significant amount of liposomes were taken up by the organs of the mononuclear phagocyte system (liver and spleen). Intense renal excretion was also observed during the entire experiment period. Moreover, the liposome uptake by the infectious focus was significantly high. These results show that long-circulating and alendronate-coated liposomes containing (99m)technetium-radiolabeled ceftizoxime have a tropism for infectious foci.
authors.affiliation: Department of Pharmaceutical Products, Faculty of Pharmacy, Belo Horizonte, Minas Gerais, Brazil.
authors.forename: Diego dos Santos
authors.initials: Ddos S
authors.lastname: Ferreira
authors.affiliation: Department of Pharmaceutical Products, Faculty of Pharmacy, Belo Horizonte, Minas Gerais, Brazil.
authors.forename: Fernanda Alves
authors.initials: FA
authors.lastname: Boratto
authors.affiliation: Department of Clinical and Toxicological Analyses, Faculty of Pharmacy, Belo Horizonte, Minas Gerais, Brazil.
authors.forename: Valbert Nascimento
authors.initials: VN
authors.lastname: Cardoso
authors.affiliation: Veterinary School, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.
authors.forename: Rogéria
authors.initials: R
authors.lastname: Serakides
authors.affiliation: Department of Clinical and Toxicological Analyses, Faculty of Pharmacy, Belo Horizonte, Minas Gerais, Brazil.
authors.forename: Simone Odília
authors.initials: SO
authors.lastname: Fernandes
authors.affiliation: Department of Pharmaceutical Products, Faculty of Pharmacy, Belo Horizonte, Minas Gerais, Brazil.
authors.forename: Lucas Antônio Miranda
authors.initials: LA
authors.lastname: Ferreira
authors.affiliation: Department of Pharmaceutical Products, Faculty of Pharmacy, Belo Horizonte, Minas Gerais, Brazil.
authors.forename: Mônica Cristina
authors.initials: MC
authors.lastname: Oliveira
mesh_terms: D019386:Alendronate / Q000737:chemistry / Q000493:pharmacokinetics; D000818:Animals; D015296:Ceftizoxime / Q000031:analogs & derivatives* / Q000737:chemistry / Q000493:pharmacokinetics; D008081:Liposomes / Q000737:chemistry / Q000493:pharmacokinetics; D015609:Organotechnetium Compounds / Q000737:chemistry / Q000493:pharmacokinetics; D010019:Osteomyelitis / Q000175:diagnosis / Q000378:metabolism / Q000473:pathology; D051381:Rats; D017208:Rats, Wistar
chemical_list: D008081:Liposomes; D015609:Organotechnetium Compounds; C510184:technetium 99m ceftizoxime; D015296:Ceftizoxime; D019386:Alendronate
keywords: bone infection diagnosis; bone targeting; radiolabeled antibiotics; scintigraphic imaging
references.citation: Curr Cancer Drug Targets. 2010 Nov;10(7):649-59
references.pmid: 20578992
references.citation: Biochim Biophys Acta. 1994 Feb 23;1190(1):99-107
references.pmid: 8110825
references.citation: Proc Natl Acad Sci U S A. 2014 Jul 15;111(28):10287-92
references.pmid: 24982170
references.citation: Int J Pharm. 2007 Mar 1;331(2):224-7
references.pmid: 17150316
references.citation: Mol Pharm. 2013 Jan 7;10(1):319-28
references.pmid: 23259920
references.citation: Pharmacol Res. 2010 Aug;62(2):90-9
references.pmid: 20380880
references.citation: Adv Drug Deliv Rev. 1999 Apr 5;37(1-3):13-32
references.pmid: 10837724
references.citation: Infect Dis Clin North Am. 2006 Dec;20(4):789-825
references.pmid: 17118291
references.citation: Bioorg Med Chem Lett. 2009 Aug 1;19(15):4148-50
references.pmid: 19523821
references.citation: Rev Esp Med Nucl. 2000 Dec;19(7):479-83
references.pmid: 11171504
references.citation: Nucl Med Biol. 2014 May;41 Suppl:e66-74
references.pmid: 24485990
references.citation: Cell Microbiol. 2007 Oct;9(10):2323-33
references.pmid: 17645552
references.citation: Biosci Rep. 2002 Apr;22(2):129-50
references.pmid: 12428898
references.citation: Eur J Pharm Sci. 2013 Jan 23;48(1-2):282-90
references.pmid: 23178339
references.citation: AAPS J. 2007;9(2):E128-47
references.pmid: 17614355
references.citation: Radiol Clin North Am. 2001 Jul;39(4):653-71
references.pmid: 11549164
references.citation: Bioorg Med Chem. 2011 Jun 1;19(11):3520-6
references.pmid: 21536448
references.citation: J Microencapsul. 2000 Jul-Aug;17(4):459-65
references.pmid: 10898086
references.citation: Osteoporos Int. 2008 Jun;19(6):733-59
references.pmid: 18214569
references.citation: Int J Nanomedicine. 2012;7:5889-900
references.pmid: 23226020
references.citation: J Nucl Med. 1996 Aug;37(8):1392-7
references.pmid: 8708782
references.citation: Q J Nucl Med Mol Imaging. 2006 Jun;50(2):147-52
references.pmid: 16770305
references.citation: Langmuir. 2014 May 6;30(17):4997-5004
references.pmid: 24716859
references.citation: J Nucl Med Technol. 2004 Jun;32(2):47-57; quiz 58-9
references.pmid: 15175400
references.citation: Nucl Med Commun. 2008 Sep;29(9):830-6
references.pmid: 18677212
references.citation: Eur J Nucl Med. 2001 Feb;28(2):241-52
references.pmid: 11303896
references.citation: Q J Nucl Med Mol Imaging. 2006 Sep;50(3):167-92
references.pmid: 16868532
references.citation: Inflamm Res. 2001 Feb;50(2):55-64
references.pmid: 11289655
references.citation: Calcif Tissue Int. 2004 Dec;75(6):451-61
references.pmid: 15332174
references.citation: Bioorg Med Chem Lett. 2012 Jul 15;22(14):4605-8
references.pmid: 22726927
references.citation: Semin Nucl Med. 2000 Apr;30(2):147-8
references.pmid: 10787196
references.citation: Adv Drug Deliv Rev. 2014 Feb;66:2-25
references.pmid: 24270007
references.citation: J Nucl Med. 2001 Aug;42(8):1257-64
references.pmid: 11483689
references.citation: Radiologe. 1996 Oct;36(10):781-5
references.pmid: 9036415
references.citation: J Control Release. 1999 Nov 1;62(1-2):245-51
references.pmid: 10518657
references.citation: J Nucl Med. 1998 Jun;39(6):1089-94
references.pmid: 9627351